HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting

December 06, 2023 00:30:42
HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting
COR2ED - Oncology Medical Conversation
HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting

Dec 06 2023 | 00:30:42

/

Show Notes

Prof. Josep Llovet and Prof. Stephen L. Chan discuss a very interesting topic about the use of the VEGFR TKIs monotherapy in the treatment of unresectable or advanced HCC in the first-line setting. They will go into details about who can benefit from monotherapy and will share the current guidance on the implementation of the dosing strategies for the management of toxicity in the clinical practice. They discuss first line monotherapy with TKI (lenvatinib or sorafenib) for patients who are not suitable for the treatment with atezo-bev combination (around 20% of the patients) which is the current standard of care. They summarise the HCC patients who are not ideal for this I/O combination such as HCC patients with liver transplantation, high bleeding risk, impaired liver function or severe autoimmune disease. The experts discuss about which patients can benefit from TKI and provide a summary of efficacy data and safety profile from various pivotal clinical studies (including SHARP, REFLECT, IMbrave150) as well as real-world data. Dosing-strategies for VEGFR-TKIs and management of AEs are discussed as well as guideline recommendations. Finally, the experts discuss key developments over the next few years focusing on the new immunotherapy combinations approach that could become new standard of care.

Other Episodes

Episode

May 15, 2024 00:25:30
Episode Cover

Understanding the needs of different patient populations in colorectal cancer

Do you understand the needs of different patient groups with colorectal cancer?  Do you know about the barriers to treatment experienced by different ethnicities,...

Listen

Episode

December 06, 2023 00:25:18
Episode Cover

Upper GI cancer Highlights from ASCO GI 2023 - Part 1

This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023.  Dr Nataliya Uboha (University of Wisconsin, USA)...

Listen

Episode

January 07, 2025 00:20:19
Episode Cover

Intermediate HCC – treatment options and strategies

In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr...

Listen